

Sudan

Tuberculosis profile

Population 2016

40 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	5.6 (3–9.1)	14 (7.5–23)
Mortality (HIV+TB only)	0.28 (0.098–0.57)	0.72 (0.25–1.4)
Incidence (includes HIV+TB)	32 (18–51)	82 (46–129)
Incidence (HIV+TB only)	0.83 (0.54–1.2)	2.1 (1.4–3)
Incidence (MDR/RR-TB)**	1.2 (0.58–1.9)	3.1 (1.5–4.7)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	2.2 (1.1–3.4)	12 (5.7–17)	14 (6.8–21)
Males	2.3 (1.1–3.5)	16 (8–25)	19 (9.2–28)
Total	4.6 (2.2–6.9)	28 (14–42)	32 (18–51)

TB case notifications, 2016

Total cases notified	21 084
Total new and relapse	20 477
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	17%
- % pulmonary	76%
- % bacteriologically confirmed among pulmonary	46%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	63% (40–110)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.19 (0.08–0.34)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	253	7%
- on antiretroviral therapy		

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			600 (410–780)
Estimated % of TB cases with MDR/RR-TB	2.9% (1.7–4.1)	13% (8.6–17)	
% notified tested for rifampicin resistance	<1%	27%	660
MDR/RR-TB cases tested for resistance to second-line drugs			132
Laboratory-confirmed cases		MDR/RR-TB: 143, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 135, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2015	79%	6 083
Previously treated cases registered in 2015		
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014	74%	74
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2017

National TB budget (US\$ millions)	12
Funding source: 21% domestic, 79% international, 0% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



New cases
Previously treated cases
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded
Funded internationally
Funded domestically